Merck
CN

A0100000

乙酰唑胺

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
5-乙酰胺基-1,3,4-噻二唑-2-磺酰胺, N-(5-[氨基磺酰基]-1,3,4-噻二唑-2-基)乙酰胺, N-(5-氨磺酰基-1,3,4-噻二唑-2-基)乙酰胺
经验公式(希尔记法):
C4H6N4O3S2
CAS号:
分子量:
222.25
MDL编号:
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API family

acetazolamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES string

CC(=O)Nc1nnc(s1)S(N)(=O)=O

InChI

1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)

InChI key

BZKPWHYZMXOIDC-UHFFFAOYSA-N

Gene Information

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

应用

碳酸酐酶抑制剂;增加脑血流量。

生化/生理作用

通过与水通道蛋白相互作用抑制膜的水渗透性

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Eye Irrit. 2 - Skin Irrit. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

为方便起见,与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

Tsogyal D Latshang et al.
JAMA, 308(22), 2390-2398 (2012-12-13)
Many patients with obstructive sleep apnea syndrome (OSA) living near sea level travel to altitude, but this may expose them to hypoxemia and exacerbation of sleep apnea. The treatment in this setting is not established. To evaluate whether acetazolamide and
Paolo Salvi et al.
Hypertension (Dallas, Tex. : 1979), 61(4), 793-799 (2013-02-27)
High-altitude tourism is increasingly frequent, involving also subjects with manifest or subclinical coronary artery disease. Little is known, however, on the effects of altitude exposure on factors affecting coronary perfusion. The aim of our study was to assess myocardial oxygen
Bradley A Edwards et al.
Sleep, 36(2), 281-285 (2013-02-02)
The magnitude of the post-apnea/hypopnea ventilatory overshoot following arousal may perpetuate subsequent respiratory events in obstructive sleep apnea (OSA) patients, potentially contributing to the disorder's severity. As acetazolamide can reduce apnea severity in some patients, we examined the effect of
Özlen Güzel-Akdemir et al.
Bioorganic & medicinal chemistry, 21(6), 1386-1391 (2013-01-29)
By using phthalimido-substituted aromatic sufonamides as lead molecules, a series of new sulfonamides incorporating ortho-benzenedisulfonimide moieties have been synthesized and tested against the human (h) cytosolic carbonic anhydrase (CA, EC 4.2.1.1) isozymes hCA I and hCA II and the transmembrane
Karine Auré et al.
Neurology, 81(21), 1810-1818 (2013-10-25)
To report that homoplasmic deleterious mutations in the mitochondrial DNA MT-ATP6/8 genes may be responsible for acute episodes of limb weakness mimicking periodic paralysis due to channelopathies and dramatically responding to acetazolamide. Mitochondrial DNA sequencing and restriction PCR, oxidative phosphorylation

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门